Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma.

Trial Profile

Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Glioma; Meningioma; Neurofibromatoses
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Mar 2016 New source found and integrated (NCT01207687).
    • 21 Mar 2016 New source found and integrated (NCT01207687).
    • 14 Mar 2016 Primary endpoint has been met, (Change in hearing response, defined as increased word recognition score (WRS) above the 95% critical threshold that is maintained across two sequential evaluation time points), according to the results published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top